PHOTOCURE: DATA ON HEXVIX®/CYSVIEW® TO BE PRESENTED AT AMERICAN UROLOGICAL ASSOCIATION, SAN DIEGO, USA

Share this article
Published: 6 May 2013Medical congresses & eventsMedical Information

Oslo, Norway, May 6, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that data will be presented on Hexvix®/Cysview®, its flagship product to aid in diagnosing bladder cancer, at the American Urological Association (AUA) Annual Meeting in San Diego, USA on 6 May 2013.

Two posters will be presented:

Comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for detection of bladder cancer

A retrospective study was carried out on 62 patients with known or suspected bladder cancer. All patients had white light cystoscopy followed by photodynamic diagnostic cystoscopy (PDD) with Hexvix/Cysview. The data indicate that the greater sensitivity of Hexvix/Cysview PDD allows greater detection of tumors. Adam Kern, MD (Johns Hopkins, Baltimore, MD) will be presenting this data on 6 May at 1:00 pm.

A meta-analysis of blue light cystoscopy with hexaminolevulinate in patients with non-muscle invasive bladder cancer

The meta-analysis, which was conducted on raw data from eight Hexvix/Cysview prospective studies and included a total of 1,293 patients, confirms previous studies and indicates that Hexvix cystoscopy significantly improves the detection of bladder cancer and reduces the risk of recurrence. Leonard Gomella, MD (Thomas Jefferson, Philadelphia, PA) will be presenting this data on 6 May at 3:30 pm.

Kjetil Hestdal, President and Chief Executive Officer of Photocure, commented: "These data confirm the effectiveness of blue light cystoscopy with Hexvix/Cysview as an adjunct to white light in bladder cancer detection and the reduction in risk of recurrence. We are delighted that the organizers have accepted the data on Hexvix/Cysview for presentation at this prestigious conference."

About Hexvix®/Cysview®
Hexvix/Cysview is the first approved drug-device combination procedure for improved detection and management of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic agents. Hexvix is an approved product in Europe and the US. Photocure markets and sells Hexvix in the Nordic region, and has initiated the commercialization of Cysview directly in the US. Ipsen is commercializing Hexvix in Europe excluding Nordics.

For further information, please contact:
 
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl
Tel: +47 50 55 000, Email: ed@photocure.no

M:Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com

Notes to editors
About Photocure ASA
Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
Share this article

News and events